Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Shares of Exelixis EXEL were down 5.13% on Jan. 24, following a downgrade in rating by analysts at Oppenheimer. Oppenheimer ...

2025年，全球医药领域将迎来一系列重要趋势和突破性进展。在肿瘤学、肥胖症药物以及人工智能（AI）应用的推动下，药物创新的格局正在被重新塑造，医疗健康产业也将面临前所未有的机遇与挑战。近期，《自然》旗下的Nature Reviews Drug ...

Future Oncol. 2015;11(7):1023-1026. Tumor-negative breast cancers misclassified as HER2 negative by IHC (0 or 1+) could therefore be reclassified by FISH, with a remarkable impact on medical ...

2025年，全球医药领域将迎来一系列重要趋势和突破性进展。在肿瘤学、肥胖症药物以及人工智能（AI）应用的推动下，药物创新的格局正在被重新塑造，医疗健康产业也将面临前所未有的机遇与挑战。近期，《自然》旗下的Nature Reviews Drug ...

Summer V Allen; Lise Solberg Nes; Mary L Marnach; Kristen Polga; Sarah M Jenkins; Julia A Files; Ivana T Croghan; Karthik Ghosh; Sandhya Pruthi The current study sought to investigate the impact ...

DelveInsight’s, “Squamous Cell Carcinoma Pipeline Insight” report provides comprehensive insights about 75+ companies and 80+ ...

Roche claimed FDA approval for Tecentriq (atezolizumab) in the US last year ... While Merck's Keytruda (pembrolizumab) dominates first-line treatment of more advanced NSCLC, it has been behind ...

It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...

At the final analysis, the coprimary endpoint of overall survival was not met. Topline data were announced from a phase 3 trial evaluating pembrolizumab (Keytruda ®) plus lenvatinib (Lenvima ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...

During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes presented at ESMO 2024 and how they fit into the treatment paradigm for patients ...